引言在全球制药行业的版图中，丹麦巨头诺和诺德（Novo Nordisk A/S，股票代码：NVO）长期以来以其在糖尿病治疗领域的领导地位而闻名遐迩。然而，近年来，凭借其突破性的胰高血糖素样肽-1（GLP-1）类药物，尤其是司美格鲁肽（Semaglutide）旗下的Ozempic（用于糖尿病）和Wegovy（用于肥胖症），诺和诺德已成功转型，在蓬勃发展的减肥药市场中建立起一个令人瞩目的“帝国”。司...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.